Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05101460 · ClinicalTrials.gov registry record

An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant

A clinical trial of Lung Transplant, sponsored by XVIVO Perfusion.

Recruiting
Registry status
315
Enrollment target
1
Study location

NCT05101460: Recruiting study of Lung Transplant, sponsored by XVIVO Perfusion.

NCT05101460 is a study of Lung Transplant that is actively recruiting participants, run by XVIVO Perfusion. The registered enrollment target is 315 participants, below the 1,255-participant average among 15 other Lung Transplant trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05101460, a study of Lung Transplant, is actively recruiting participants, sponsored by XVIVO Perfusion.

RECRUITING
Registry status
315 participants
Enrollment target
1
Study location

Study Summary

The XVIVO Registry is to collect standard of care clinical data from "all-comers" who are transplanted with an EVLP lung treated with the XVIVO Perfusion System™ in order to assess the long-term performance of the device, and monitor device-related serious adverse events. In addition, 4 and 5-year UNOS registry data of the 126 subjects who received an EVLP transplant under the NOVEL and NOVEL Extension studies are provided as part of the long-term safety and quality of life data. In addition, 4 and 5-year UNOS registry data of the 126 subjects who received an EVLP transplant under the NOVEL and NOVEL Extension studies are provided as part of the long-term safety and quality of life data.

Primary Outcome

Primary effectiveness endpoint

Conditions Studied

Interventions

  • DEVICE XVIVO Perfusion System (XPS™) with STEEN Solution™

Study Locations (1)

Ohio

  • Cleveland Clinic Foundation - Cleveland

Trial Details

FieldValue
Enrollment Target 315 participants
Start Date 2019-10-29
Est. Completion 2029-04-24
XVIVO Perfusion

3 total trials

What NCT05101460 shows while recruiting

NCT05101460 is an observational study that tracks outcomes without assigning an intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, below the 1,255-participant average among 15 other Lung Transplant trials with a reported enrollment target (75% lower).

The record links to 1 condition, with Lung Transplant appearing as the primary indexed condition, and to 1 intervention - of which XVIVO Perfusion System (XPS™) with STEEN Solution™ is the first listed.

NCT05101460 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT05101460 about?

NCT05101460 is a clinical study titled "An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant". The XVIVO Registry is to collect standard of care clinical data from "all-comers" who are transplanted with an EVLP lung treated with the XVIVO Perfusion System™ in order to assess the long-term performance of the device, and monitor device-related serious adverse events. In addition, 4 and 5-year U...

What is the current status of trial NCT05101460?

This trial is currently recruiting. The enrollment target is 315 participants. The study started on 2019-10-29. Estimated completion is 2029-04-24.

What conditions does trial NCT05101460 study?

This clinical trial studies the following conditions: Lung Transplant.

What interventions are being tested in trial NCT05101460?

The interventions under investigation include: XVIVO Perfusion System (XPS™) with STEEN Solution™ (DEVICE).

Who is sponsoring clinical trial NCT05101460?

This trial is sponsored by XVIVO Perfusion, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05101460 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Transplant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05101460's enrollment target sits among peer trials

315 5th of 15 higher than 11 of 15 other Lung Transplant trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04812366 · 315 participants · Phase 2

    Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

  • NCT05897320 · 315 participants · Phase 3

    A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

  • NCT06439082 · 315 participants · Phase 3

    A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

  • NCT06846320 · 315 participants · Phase 2

    Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05101460, the US trial registry maintained by the National Library of Medicine. NCT05101460 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.